Purpose: The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide. Methods: Etoposide plasma levels were determined by HPLC. Results: The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses. Conclusions: The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.